PROPOSAL TWO:
APPROVAL OF THE ISSUANCE OF SHARES OF COMMON STOCK UPON EXERCISE OF THE INDUCEMENT WARRANTS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635
General
On September 29, 2024, we commenced a warrant inducement offering with the holders of outstanding warrants to purchase 5,079,244 shares of common stock consisting of: (i) common stock purchase warrants to purchase 3,245,744 shares of common stock issued on or about November 29, 2023 and (ii) common stock purchase warrants to purchase 1,833,500 shares of common stock issued on or about April 9, 2024 (collectively, the “Existing Warrants”), which were exercisable for an equal number of shares of common stock at an exercise price of $0.228. In the warrant inducement offering, we offered the holders a period of time (the “Inducement Period”) whereby we agreed to issue new warrants (to purchase up to a number of shares of common stock equal to 200% of the number of shares of common stock issued pursuant to the exercise by the holders of the Existing Warrants during the Inducement Period, for cash, at a reduced exercise price equal to the Nasdaq Minimum Price (as defined in the as defined in Nasdaq Listing Rule 5635(d)).
On September 29, 2024, we entered into warrant inducement agreements with certain holders of the Existing Warrants to purchase an aggregate of 5,079,244 shares of common stock at an exercise price of $0.228. Pursuant to the warrant inducement agreements, the exercising holders of the Existing Warrants received 10,158,488 Common Warrants with an exercise price of $1.00 per share and 304,755 Placement Agent Warrants with an exercise price of $1.25 per share (collectively, the “Inducement Warrants”), and we received aggregate gross proceeds of approximately $1.1 million from the exercise of the Existing Warrants.
The Inducement Warrants are not exercisable unless and until our stockholders approve this Proposal 2 to approve the issuance of the shares of common stock underlying the Inducement Warrants pursuant to applicable Nasdaq rules. The Inducement Warrants may be exercised, in certain circumstances, on a cashless basis. A holder of such warrants may also effect an “alternative cashless exercise” on or after the initial exercise date. In such event, the aggregate number of shares of common stock issuable in such alternative cashless exercise pursuant to any given notice of exercise electing to effect an alternative cashless exercise shall equal the product of (x) the aggregate number of shares of common stock that would be issuable upon exercise of the warrant in accordance with the terms of the warrant if such exercise were by means of a cash exercise rather than a cashless exercise and (y) 0.75.
The Inducement Warrants are subject to adjustment in certain circumstances, including upon any subsequent equity sales at a price per share lower than the then effective exercise price of such warrants, then such exercise price shall be lowered to such price at which the shares were offered. Additionally, if at any time on or after the date of issuance there occurs a share combination event such as stock split, stock dividend, stock combination, recapitalization or other similar transaction involving our common stock, such as the proposed Reverse Split included herein in Proposal 1, the lowest daily VWAP during the period commencing five (5) consecutive trading days immediately preceding and the five consecutive trading days immediately following such event is less than the exercise price of the Inducement Warrants then in effect, then such exercise price shall be reduced to the lowest daily VWAP during such five (5)-day period and the number of shares of common stock issuable upon exercise will be increased such that the aggregate exercise price, after taking into account the decrease, shall be equal to the aggregate exercise price on the issuance date. Section 3(b) or Section 3(f) of the Warrants provides as follows:
b)
Subsequent Equity Sales. If the Company or any Subsidiary thereof, as applicable, at any time while this Warrant is outstanding, shall sell, enter into an agreement to sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or Common Stock Equivalents, at an effective price per share less than the Exercise Price then in effect (such lower price, the “Base Share Price” and such issuances collectively, a “Dilutive Issuance”) (it being understood and agreed that if the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive shares of Common Stock at an effective price per share that is less than the Exercise Price, such issuance shall be deemed